Latest news with #GNA
Fibre2Fashion
12-06-2025
- Business
- Fibre2Fashion
INDA & EDANA approve formation of Global Nonwoven Alliance
The Boards of Directors of INDA and EDANA have officially approved the formation of the Global Nonwoven Alliance (GNA) and have concurrently agreed to become its founding members. Both Boards have also approved a motion authorizing each organization to appoint six representatives from each founding organization – current chair and 5 additional representatives. INDA and EDANA have officially formed the Global Nonwoven Alliance (GNA), each appointing six board members. GNA, a US-based non-profit, will unify global efforts to boost innovation, efficiency, and growth in the nonwovens industry. Both groups remain independent but will align leadership and programmes to address global challenges collaboratively. This move marks a major milestone in the collaborative vision outlined in the organizations' jointly signed Letter of Intent from September 2024. The Board votes follow extensive planning and consultation and includes the recommendation to formally establish GNA as a non-profit association under the laws of the United States. By aligning strategic resources and deepening collaboration, the GNA will provide a unified and coordinated approach to the key opportunities and challenges facing the global nonwovens industry. The Alliance is designed to accelerate innovation, improve operational efficiency, expand international reach, and foster long-term industry growth—all while strengthening the services and support delivered to members at both regional and global levels. Under the GNA framework, INDA and EDANA will continue to operate as independent legal entities, maintaining their regional focus and advocacy efforts. As founding members, however, both organizations will participate in aligning leadership, staffing, and programmatic initiatives to advance shared objectives and cross-border priorities. In the immediate term, INDA and EDANA will focus on laying a strong foundation for GNA, including establishing the organization and solidifying its governance structure. Looking ahead, Allied Membership is expected to be open to any not-for- profit trade, industry, or professional association whose mission aligns with that of the founding members—offering an inclusive platform for broader collaboration across the global nonwovens value chain. 'The formation of GNA is a milestone for our industry. By working together across regions, we can accelerate innovation, speak with a stronger voice globally, and deliver even greater value to our members,' said Tony Fragnito, President of INDA. 'This is not a merger—it's a strategic alliance built on mutual respect and a shared commitment to the future of nonwovens.' 'With the creation of GNA, we are positioning the nonwovens industry to meet global challenges with greater unity and impact,' said Murat Dogru, General Manager of EDANA. 'This collaborative structure allows us to scale our efforts, strengthen our influence, and pursue solutions that benefit our members worldwide.' GNA will be governed by a Board composed of six members from each founding organization –five appointed representatives plus the current Chair–, ensuring balanced representation and a regional perspective. This governance structure will promote transparency, long-term strategic alignment, and organizational stability while guiding shared policies, priorities, and programs. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. Fibre2Fashion News Desk (HU)
Yahoo
09-06-2025
- Health
- Yahoo
Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes
Poster Presentation Reviews the Hemopurifier® Affinity Resin's Ability to Bind Extracellular Vesicles in Long COVID Samples SAN DIEGO, June 9, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel & Spa, Santa Fe, NM, United States, August 10-13,2025 ( Long COVID refers to persistent symptoms following acute SARs-CoV-2 infection (COVID-19). These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain and cognitive difficulties such as "brain fog" - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the United States alone with a projected economic burden of $2 billion for those with symptoms lasting a year. Despite over $1 billion allocated to Long COVID research funding, no treatment has proven effective. Extracellular vesicles (EVs), nanoparticles 50-500nm in diameter, released from all cell types and involved in cell-to-cell communication, have been implicated in the pathogenesis of Long COVID. EVs have been found to contain viral particles and other cargo associated with abnormal blood clotting and inflammation. Aethlon Medical's Hemopurifier® is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin (GNA), previously found to bind to the sugar mannose. The Hemopurifier has previously been shown to remove EVs in a patient with severe acute COVID-19 infection. Aethlon Medical collaborated with the University of California San Francisco Medical Center Long COVID clinic to evaluate plasma samples from participants with Long COVID and control participants who had fully recovered from COVID-19 in order to examine whether individuals with Long COVID would have EVs with the mannose target on their surface that would bind to the affinity resin in the device. The data to be presented will review the binding of both larger and smaller EVs to GNA lectin and the lectin-based affinity resin, respectively. Presentation details and times are as follows: Title: Extracellular Vesicles from Participants with Long COVID are Mannosylated and Bind to the Galanthus Nivalis Agglutinin Resin in the Aethlon Hemopurifier® Authors: Miguel Pesqueira1, Rosalia de Necochea Campion1, Thomas Dalhuisen2, Emily A. Fehrman2, Jeffrey N. Martin2, Timothy J. Henrich2, Steven G. Deeks2, Michael J. Peluso2, Steven P. LaRosa1 Aethlon Medical Inc., San Diego, CA, USA University of California, San Francisco, San Francisco, CA, USA Presenter: Steven P. LaRosa, M.D, Chief Medical Officer, Aethlon Medical, Number: 2001Date and Time: August 12, 2025, 1930, MDT. This poster will be available following the meeting on the Aethlon Medical, Inc. corporate website at About Aethlon and the Hemopurifier® Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation, and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additional information can be found at Company Contact:Jim FrakesChief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. Jfrakes@ Investor Contact:Susan NoonanS.A. Noonan Communications, LLCsusan@ View original content: SOURCE Aethlon Medical, Inc. Sign in to access your portfolio
Yahoo
09-06-2025
- Health
- Yahoo
Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes
Poster Presentation Reviews the Hemopurifier® Affinity Resin's Ability to Bind Extracellular Vesicles in Long COVID Samples SAN DIEGO, June 9, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel & Spa, Santa Fe, NM, United States, August 10-13,2025 ( Long COVID refers to persistent symptoms following acute SARs-CoV-2 infection (COVID-19). These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain and cognitive difficulties such as "brain fog" - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the United States alone with a projected economic burden of $2 billion for those with symptoms lasting a year. Despite over $1 billion allocated to Long COVID research funding, no treatment has proven effective. Extracellular vesicles (EVs), nanoparticles 50-500nm in diameter, released from all cell types and involved in cell-to-cell communication, have been implicated in the pathogenesis of Long COVID. EVs have been found to contain viral particles and other cargo associated with abnormal blood clotting and inflammation. Aethlon Medical's Hemopurifier® is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin (GNA), previously found to bind to the sugar mannose. The Hemopurifier has previously been shown to remove EVs in a patient with severe acute COVID-19 infection. Aethlon Medical collaborated with the University of California San Francisco Medical Center Long COVID clinic to evaluate plasma samples from participants with Long COVID and control participants who had fully recovered from COVID-19 in order to examine whether individuals with Long COVID would have EVs with the mannose target on their surface that would bind to the affinity resin in the device. The data to be presented will review the binding of both larger and smaller EVs to GNA lectin and the lectin-based affinity resin, respectively. Presentation details and times are as follows: Title: Extracellular Vesicles from Participants with Long COVID are Mannosylated and Bind to the Galanthus Nivalis Agglutinin Resin in the Aethlon Hemopurifier® Authors: Miguel Pesqueira1, Rosalia de Necochea Campion1, Thomas Dalhuisen2, Emily A. Fehrman2, Jeffrey N. Martin2, Timothy J. Henrich2, Steven G. Deeks2, Michael J. Peluso2, Steven P. LaRosa1 Aethlon Medical Inc., San Diego, CA, USA University of California, San Francisco, San Francisco, CA, USA Presenter: Steven P. LaRosa, M.D, Chief Medical Officer, Aethlon Medical, Number: 2001Date and Time: August 12, 2025, 1930, MDT. This poster will be available following the meeting on the Aethlon Medical, Inc. corporate website at About Aethlon and the Hemopurifier® Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation, and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additional information can be found at Company Contact:Jim FrakesChief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. Jfrakes@ Investor Contact:Susan NoonanS.A. Noonan Communications, LLCsusan@ View original content: SOURCE Aethlon Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
West Australian
05-06-2025
- Sport
- West Australian
Chapman Valley Football Club and Geraldton Netball Association join forces for FightMND's Big Freeze
For the first time, the Geraldton Netball Association is joining forces with the Chapman Valley Football Club to raise funds for charity FightMND's Big Freeze. For the past five years, the Chapman Valley Football Club has hosted the Big Freeze in the Valley, which has been a fan favourite event for Royals' members and Great Northern Football League fans. Chapman Valley Football Club president Mark Houston said the Big Freeze had grown into something huge, with fans from all over the GNFL marking it down as a marquee event for the league and the club. 'When we first started we weren't quite sure of how it would be received by the public, but now it has grown to something that everyone really looks forward to,' he said. 'It certainly has turned into probably our biggest event in the year for the club. 'Juniors now get involved so it has turned into something for everyone.' With the event's growing popularity, the Geraldton Netball Association has jumped on board and will be hosting a Big Freeze event of its own. The GNA will be hosting two ice bucket events — Bucket Freeze — in the lead-up to the Big Freeze Slide. Jodie Tirant, of the GNA, said the association was looking forward to bringing the event to the courts as participants aimed to raise funds for a great cause. 'It is such a good kind of event that raises funds for a great cause, and we just wanted to create some atmosphere as well for a good cause,' she said. 'We are looking at having one slider from every club in the association, and really get everyone involved in the event and raise funds. 'I think it will attract a fair bit of attention given that we have so many people down at the courts over the days that the Big Freeze events are on. 'Our goal is to have a bit of fun, get everyone involved, and get some money raised for such a great cause. 'Mark and Chapman Valley have set the bar and have set a great example for us to follow, and we hope to continue it from this year on into the future.' The GNA will hold its Bucket Freeze events on Saturday, June 21 and Tuesday, June 24 in the lead-up to the Big Freeze Slide on Wednesday, June 25. The Chapman Valley Football Club will host the Big Freeze game against Towns before the Big Freeze Slide on Saturday, June 21 at Mazzuchelli Oval.
Libya Review
05-06-2025
- Politics
- Libya Review
Will Libya's Parliament Ratify Maritime Deal with Turkey?
The Libyan House of Representatives is reportedly considering ratifying a contentious maritime agreement with Turkey, according to Greece's Ekathimerini newspaper. The move could significantly reshape geopolitical dynamics in the Eastern Mediterranean. The maritime memorandum of understanding (MoU) was originally signed in 2019 between Turkey and the outgoing Government of National Accord (GNA) in Tripoli. The agreement demarcates maritime boundaries, granting Turkey access to a vast economic zone believed to contain untapped energy resources. At the time, the deal was met with strong opposition from several regional players. Greece, Cyprus, and Egypt all condemned the agreement as illegal, arguing it violated international maritime law and infringed on their territorial waters. Libya's eastern-based authorities, including the Tobruk parliament, also rejected the GNA's authority to sign such international deals. Parliament Speaker Ageela Saleh had previously labelled the Turkey-GNA agreement 'null and void', calling it a breach of Libyan sovereignty. However, recent developments suggest a potential shift in position. Reports indicate that the House of Representatives has formed a committee tasked with reviewing—and possibly ratifying—the agreement. If confirmed, this would represent a major political reversal by the eastern Libyan bloc. It would also bring both major Libyan factions—those in Tripoli and Tobruk—into alignment with Turkey's maritime claims. Such a step would challenge Greece's bilateral maritime agreement with Egypt and complicate ongoing efforts to explore and exploit natural gas reserves in the Eastern Mediterranean. Turkey has deepened its engagement with eastern Libyan authorities in recent years. Ankara hosted Haftar's son, Saddam, in previous visits and extended humanitarian aid during times of crisis. These moves are widely viewed as part of a broader strategy to expand Turkish influence in the region. The potential ratification of the 2019 maritime MoU by the Libyan parliament would mark a turning point in regional diplomacy. It could further escalate tensions over Mediterranean energy resources, while cementing Turkey's strategic foothold across Libya's political divide. Such a development would likely provoke sharp reactions from Athens and Cairo, who have long opposed Ankara's assertive maritime policies. Tags: GNAGreecelibyaLibyan parliamentMaritime Deal
